ACTIVE WATCHFUL WAITING
Safeguarding children from institutional harm
Complete absence of risk and harm disclosure
Kaleido Health Centre advertises "Gender Affirming Hormone Therapy" as a current service. Yet across the entire public website—including the Gender Affirmation page, GP Services, Child/Family/Youth, Mental Health, Q&A, Home, and Book Now pages—there is not a single mention of treatment risks.
What's missing
Independent evidence reviews identify these as material risks that reasonable consumers—including parents of minors—would need to know before consenting to hormone therapy:
-
Cardiovascular risks: Increased risk of blood clots, stroke, and heart disease
-
Bone health risks: Reduced bone density, increased fracture risk, especially with early puberty suppression
-
Fertility impairment: Permanent or long-term reduction in fertility; some effects may be irreversible
-
Sexual function impacts: Reduced libido, sexual dysfunction, impaired sexual development if started young
-
Cancer risks: Potential increased risks for certain hormone-dependent cancers
-
Liver damage risks: Elevated liver enzymes, potential liver toxicity with some formulations
-
Irreversibility of certain effects: Voice deepening (testosterone), breast development (oestrogen), genital development changes
None of this information appears anywhere on Kaleido's public website.
The legal issue
Independent evidence reviews identify these as material risks that reasonable consumers—including parents of minors—would need to know before consenting to hormone therapy:
Section 133(1)(a) of the Health Practitioner Regulation National Law prohibits advertising that is false, misleading, or deceptive.
Advertising medical interventions with permanent effects while systematically omitting material risk information is misleading by omission.
Even the AusPATH 2025 Standards of Care—which Kaleido claims to follow—require risk disclosure during consent processes. The clinic's public website is part of that consent process. It's often the first place parents and young people go to understand what these treatments involve.
The complete absence of risk information undermines consumers' ability to provide genuinely informed consent.
Evidence detail
What the audit says "Complete absence of risk disclosure on public website, despite offering 'Gender Affirming Hormone Therapy' as a current service. No mention of cardiovascular risks, bone health risks, fertility impairment, sexual function impacts, cancer risks, liver damage risks, or irreversibility of certain effects." —Kaleido Health Centre Informed Consent Compliance Audit, Section 3 (8 May 2026)
Assessment criteria The audit assessed the clinic's website against: • Australian Consumer Law sections 18 and 29 • Health Practitioner Regulation National Law section 133 • Independent systematic reviews establishing what risks are material (Cass 2024, York/ADC 2024, US HHS 2025, Ruuska 2026)
For Parents
What this means for you
There is zero mention of cardiovascular risks, bone density loss, fertility impairment, sexual function changes, or irreversibility—even though the clinic offers hormone therapy.
You cannot give truly informed consent if the risks are never discussed publicly.
What to do: Bring this audit to your GP or paediatrician appointment. Ask them to explain every risk listed above before you consider any medical pathway. You have the right to full information.
For Mps
Policy & regulatory issue
AHPRA Finding 3 documents a complete absence of material risk disclosure—a clear breach of Section 133(1)(a) of the National Law.
Even the standards the clinic cites (AusPATH) require risk information during consent. Public websites are part of the informed consent process and must meet National Law standards.
What's needed: AHPRA investigation of this clinic and sector-wide guidance requiring gender clinics to provide material risk disclosures with comparable prominence to benefit claims on all public-facing materials.
For Health Professionals
Clinical & professional standards issue
Material risk disclosure is foundational to informed consent. The Australian Commission on Safety and Quality in Health Care's Informed Consent Standard requires patients receive information about "material risks of the proposed treatment."
Kaleido's public website provides none. This creates a compliance gap where patients and families may arrive at consultations without basic risk awareness, undermining the informed consent process.
Professional responsibility: If you refer patients to this clinic, ensure you're independently providing comprehensive risk information. Don't assume the clinic's website has already informed them. The audit shows it hasn't.
Evidence detail
This connects to other compliance failures documented in the audit:
-
Finding 1: Overall Impression — Systematic omission across all pages creates misleading overall impression
-
Finding 2: Unqualified Claims — "Safe" and "evidence-based" claims with no caveats about evidence uncertainty
-
Findings 5 & 6: Irreversibility & Fertility — No disclosure of permanent effects or fertility impacts despite offering hormones